专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2009109635A2 NOVEL ANTIGEN BINDING DIMER-COMPLEXES, METHODS OF MAKING AND USES THEREOF 审中-公开
标题翻译：新型抗原结合二聚体复合物，其制备方法和用途
公开(公告)号：WO2009109635A2
公开(公告)日：2009-09-11
申请号：PCT/EP2009/052629
申请日：2009-03-05
申请人： ABLYNX NV , CASTEELS, Peter , LAUWEREYS, Marc Jozef , STANSSENS, Patrick , LABEUR, Christine , BOUTTON, Carlo , BRIGÉ, Anne , HOOGENBOOM, Hendricus Renerus Jacobus Mattheus , BEINAERT, Els Anna Alice
发明人： CASTEELS, Peter , LAUWEREYS, Marc Jozef , STANSSENS, Patrick , LABEUR, Christine , BOUTTON, Carlo , BRIGÉ, Anne , HOOGENBOOM, Hendricus Renerus Jacobus Mattheus , BEINAERT, Els Anna Alice
IPC分类号： C07K16/00 , C07K16/22 , C07K16/28 , C07K16/36 , C07K16/18
CPC分类号： C07K16/00 , C07K16/18 , C07K16/22 , C07K16/2866 , C07K16/36 , C07K2317/22 , C07K2317/569 , C07K2317/626
摘要： In a broad aspect the present invention generally relates to novel dimer-complexes (herein called "non-fused-dimers" or NFDs) comprising single variable domains, methods of making these complexes and uses thereof. These non-covalently bound dimer-complexes consist of two identical monomers that each comprises of one or more single variable domains (homodimers) or of two different monomers that each comprises on or more single variable domains (heterodimers). The subject NFDs have typically altered e.g. improved binding characteristics over their monomeric counterpart. The NFDs of the invention may further be engineered through linkage by a flexible peptide or cysteines in order to improve the stability. This invention also describes conditions under which such NFDs are formed and conditions under which the formation of such dimers can be avoided.
摘要翻译：在广义方面，本发明一般涉及包含单个可变结构域的新型二聚体复合物（本文称为“非融合二聚体”或NFD），制备这些复合体的方法及其用途。这些非共价结合的二聚体复合物由两个相同的单体组成，每个单体包含一个或多个单可变结构域（同二聚体）或两个不同的单体，每个单体包含一个或多个单可变结构域（异二聚体）。目标NFD典型地改变了例如改善了与其单体对应物的结合特性。为了提高稳定性，本发明的NFD可以进一步通过一种或多种柔性肽的连接进行工程改造。本发明还描述了形成这种NFD的条件和可以避免形成这种二聚体的条件。

2. 发明申请

WO2010142534A1 BIPARATOPIC PROTEIN CONSTRUCTS DIRECTED AGAINST IL-23 审中-公开
标题翻译：针对IL-23指导的BIPARATOPIC蛋白质构建体
公开(公告)号：WO2010142534A1
公开(公告)日：2010-12-16
申请号：PCT/EP2010/057341
申请日：2010-05-27
申请人： ABLYNX NV , SAUNDERS, Michael John Scott , BLANCHETOT, Christophe , BOUTTON, Carlo , ROMMELAERE, Heidi , DE HAARD, Johannes Joseph Wilhelmus , DE BRABANDERE, Veronique , LAUWEREYS, Marc Jozef , MORIZZO, Erika , UNION, Ann , VERHEYDEN, Gert
发明人： SAUNDERS, Michael John Scott , BLANCHETOT, Christophe , BOUTTON, Carlo , ROMMELAERE, Heidi , DE HAARD, Johannes Joseph Wilhelmus , DE BRABANDERE, Veronique , LAUWEREYS, Marc Jozef , MORIZZO, Erika , UNION, Ann , VERHEYDEN, Gert
IPC分类号： C07K16/24 , C07K16/46
CPC分类号： C07K16/244 , C07K2317/22 , C07K2317/24 , C07K2317/31 , C07K2317/32 , C07K2317/34 , C07K2317/569
摘要： Biparatopic protein constructs that are directed against IL-23, and in particular against the p19 subunit of IL-23. The constructs comprise at least a first binding domain or binding unit directed against a first defined epitope on pl9 and at least a second binding domain or binding unit directed against a second defined epitope on p19 (or the p19/p40 interface). The binding domains or binding units may in particular be a domain antibody, a single domain antibody, a dAb or a Nanobody®. The constructs and pharmaceutical compositions comprising the same can be used for the prevention and/or treatment of diseases and disorders associated with IL-23 or IL-23 mediated signaling, such as inflammation and inflammatory disorders such as colitis, Crohn's disease and IBD, infectious diseases, psioriasis, cancer, autoimmune diseases, sarcoidosis, transplant rejection, cystic Fibrosis, asthma, chronic obstructive pulmonary disease, rheumatoid arthritis, viral infection, and common variable immunodeficiency.
摘要翻译：针对IL-23，特别是针对IL-23的p19亚基的双比较性蛋白质构建体。所述构建体包含至少第一结合结构域或针对p11上的第一定义表位的第一结合结构域或至少第二结合结构域或针对p19（或p19 / p40界面）上的第二定义表位的结合单位）。结合域或结合单位特别可以是结构域抗体，单结构域抗体，dAb或纳米抗体。包含其的构建体和药物组合物可用于预防和/或治疗与IL-23或IL-23介导的信号传导相关的疾病和病症，例如炎症和炎症性疾病如结肠炎，克罗恩病和IBD，感染性疾病，精神病，癌症，自身免疫疾病，结节病，移植排斥，囊性纤维化，哮喘，慢性阻塞性肺病，类风湿性关节炎，病毒感染和常见的免疫缺陷。

3. 发明申请

WO2012175741A2 TECHNIQUES FOR PREDICTING, DETECTING AND REDUCING ASPECIFIC PROTEIN INTERFERENCE IN ASSAYS INVOLVING IMMUNOGLOBULIN SINGLE VARIABLE DOMAINS 审中-公开
标题翻译：涉及免疫球蛋白单个可变区域的测定中预测，检测和降低相关蛋白质干扰的技术
公开(公告)号：WO2012175741A2
公开(公告)日：2012-12-27
申请号：PCT/EP2012/062251
申请日：2012-06-25
申请人： ABLYNX NV , BAUMEISTER, Judith , BOUCHE, Marie-Paule, Lucienne, Armanda , BOUTTON, Carlo , BUYSE, Marie-Ange , SNOECK, Veerle , STAELENS, Stephanie
发明人： BAUMEISTER, Judith , BOUCHE, Marie-Paule, Lucienne, Armanda , BOUTTON, Carlo , BUYSE, Marie-Ange , SNOECK, Veerle , STAELENS, Stephanie
IPC分类号： C07K16/00
CPC分类号： C07K16/28 , A61K2039/505 , C07K16/00 , C07K16/2875 , C07K16/42 , C07K16/4283 , C07K2317/22 , C07K2317/31 , C07K2317/35 , C07K2317/567 , C07K2317/569 , C07K2317/92 , C07K2317/94 , C07K2319/30 , G01N33/5306 , G01N33/6854
摘要： This invention provides, and in certain specific but non-limiting aspects relates to: assays that can be used to predict whether a given ISV will be subject to protein interference as described herein and/or give rise to an (aspecific) signal in such an assay (such as for example in an ADA immunoassay). Such predictive assays could for example be used to test whether a given ISV could have a tendency to give rise to such protein interference and/or such a signal; to select ISV's that are not or less prone to such protein interference or to giving such a signal; as an assay or test that can be used to test whether certain modification(s) to an ISV will (fully or partially) reduce its tendency to give rise to such interference or such a signal; and/or as an assay or test that can be used to guide modification or improvement of an ISV so as to reduce its tendency to give rise to such protein interference or signal; - methods for modifying and/or improving ISV's to as to remove or reduce their tendency to give rise to such protein interference or such a signal; - modifications that can be introduced into an ISV that remove or reduce its tendency to give rise to such protein interference or such a signal; ISV's that have been specifically selected (for example, using the assay(s) described herein) to have no or low(er)/reduced tendency to give rise to such protein interference or such a signal; modified and/or improved ISV's that have no or a low(er)/reduced tendency to give rise to such protein interference or such a signal.
摘要翻译：本发明提供并且在某些特定但非限制性方面涉及：可用于预测给定ISV是否将如本文所述受到蛋白质干扰和/或产生（特异性）信号的测定法测定（例如在ADA免疫测定中）。这样的预测测定可以例如用于测试给定的ISV是否可能具有引起这种蛋白质干扰和/或这种信号的倾向; 选择不是或不太容易发生蛋白质干扰的ISV或给出这样的信号; 作为可用于测试对ISV的某些修改（完全或部分）是否降低其引起这种干扰或这种信号的趋势的测定或测试; 和/或作为可用于指导ISV的修饰或改进的测定或测试，以便减少引起这种蛋白质干扰或信号的趋势; - 修改和/或改进ISV以消除或减少其引起这种蛋白质干扰或这种信号的趋势的方法; - 可以引入到ISV中的修饰，其去除或减少引起这种蛋白质干扰或这种信号的趋势; 已经特别选择的ISV（例如，使用本文所述的测定）具有没有或低（呃）/降低的引起这种蛋白质干扰或这种信号的倾向; 修饰和/或改进的ISV，其没有或低（呃）/降低的趋势引起这种蛋白质干扰或这种信号。

4. 发明申请

WO2011095545A1 PEPTIDES CAPABLE OF BINDING TO SERUM ALBUMIN AND COMPOUNDS, CONSTRUCTS AND POLYPEPTIDES COMPRISING THE SAME 审中-公开
标题翻译：能够与血清白蛋白和化合物结合的蛋白质，包含其的构建体和多肽
公开(公告)号：WO2011095545A1
公开(公告)日：2011-08-11
申请号：PCT/EP2011/051559
申请日：2011-02-03
申请人： ABLYNX NV , REVETS, Hilde Adi Pierrette , BOUTTON, Carlo
发明人： REVETS, Hilde Adi Pierrette , BOUTTON, Carlo
IPC分类号： C07K14/765 , C07K16/32 , C07K16/36
CPC分类号： C07K16/18 , A61K2039/505 , C07K5/1016 , C07K5/1019 , C07K2317/569 , C07K2317/94 , C07K2318/00 , C07K2319/31
摘要： The present invention relates to amino acid sequences that are capable of binding to serum proteins; to compounds, proteins, polypeptides, fusion proteins or constructs comprising or essentially consisting of such amino acid sequences; to nucleic acids that encode such amino acid sequences, compounds, proteins, polypeptides, fusion proteins or constructs; to compositions, and in particular pharmaceutical compositions, that comprise such amino acid sequences, compounds, proteins, polypeptides, fusion proteins or constructs; and to uses of such amino acid sequences, compounds, proteins, polypeptides, fusion proteins or constructs.
摘要翻译：本发明涉及能够结合血清蛋白质的氨基酸序列; 涉及包含或基本由此类氨基酸序列组成的化合物，蛋白质，多肽，融合蛋白或构建体; 编码这种氨基酸序列的核酸，化合物，蛋白质，多肽，融合蛋白或构建体; 包括这种氨基酸序列，化合物，蛋白质，多肽，融合蛋白或构建体的组合物，特别是药物组合物; 以及这些氨基酸序列，化合物，蛋白质，多肽，融合蛋白或构建体的使用。

5. 发明申请

WO2013168108A2 CHEMOKINE RECEPTOR BINDING POLYPEPTIDES 审中-公开
标题翻译：化合物受体结合多肽
公开(公告)号：WO2013168108A2
公开(公告)日：2013-11-14
申请号：PCT/IB2013/053711
申请日：2013-05-08
申请人： NOVARTIS AG , BROWN, Zarin , BRADLEY, Michelle , CHARLTON, Steven John , VAN HEEKE, Gino Anselmus , CROMIE, Karen , DOMBRECHT, Bruno , STEFFENSEN, Soren , BAUMEISTER, Judith , BOUCHE, Marie-Paule , BOUTTON, Carlo , BUYSE, Marie-Ange , SNOECK, Veerle , STAELENS, Stephanie
发明人： BROWN, Zarin , BRADLEY, Michelle , CHARLTON, Steven John , VAN HEEKE, Gino Anselmus , CROMIE, Karen , DOMBRECHT, Bruno , STEFFENSEN, Soren , BAUMEISTER, Judith , BOUCHE, Marie-Paule , BOUTTON, Carlo , BUYSE, Marie-Ange , SNOECK, Veerle , STAELENS, Stephanie
CPC分类号： C07K16/2866 , A61K2039/505 , C07K16/468 , C07K2317/22 , C07K2317/31 , C07K2317/34 , C07K2317/35 , C07K2317/569 , C07K2317/76 , C07K2317/92 , C07K2317/94 , C07K2319/31
摘要： The present invention relates to polypeptides directed against or specifically binding to chemokine receptor CXCR2 and in particular to polypeptides capable of modulating signal transduction from CXCR2. The invention also relates to nucleic acids, vectors and host cells capable of expressing the polypeptides of the invention, pharmaceutical compositions comprising the polypeptides and uses of said polypeptides and compositions for treatment of diseases involving aberrant functioning of CXCR2.
摘要翻译：本发明涉及针对或特异性结合趋化因子受体CXCR2的多肽，特别涉及能够调节CXCR2信号转导的多肽。本发明还涉及能够表达本发明多肽的核酸，载体和宿主细胞，包含多肽的药物组合物以及用于治疗涉及CXCR2异常功能的疾病的所述多肽和组合物的用途。

6. 发明申请

WO2009127691A1 PEPTIDES CAPABLE OF BINDING TO SERUM PROTEINS AND COMPOUNDS, CONSTRUCTS AND POLYPEPTIDES COMPRISING THE SAME 审中-公开
标题翻译：能够与血清蛋白和化合物结合的蛋白质，构建物和包含其的多肽
公开(公告)号：WO2009127691A1
公开(公告)日：2009-10-22
申请号：PCT/EP2009/054533
申请日：2009-04-16
申请人： ABLYNX N.V. , REVETS, Hilde Adi Pierrette , BOUTTON, Carlo , STAELENS, Stephanie , VERHEESEN, Peter
发明人： REVETS, Hilde Adi Pierrette , BOUTTON, Carlo , STAELENS, Stephanie , VERHEESEN, Peter
IPC分类号： C07K16/18
CPC分类号： C07K16/32 , C07K14/765 , C07K16/36 , C07K2317/22 , C07K2317/565 , C07K2317/569 , C07K2319/31
摘要： The present invention relates to amino acid sequences that are capable of binding to human serum albumin; to compounds, proteins, polypeptides, fusion proteins or constructs comprising or essentially consisting of such amino acid sequences; to nucleic acids that encode such amino acid sequences, compounds, proteins, polypeptides, fusion proteins or constructs; to compositions, and in particular pharmaceutical compositions, that comprise such amino acid sequences, compounds, proteins, polypeptides, fusion proteins or constructs; and to uses of such amino acid sequences, compounds, proteins, polypeptides, fusion proteins or constructs.
摘要翻译：本发明涉及能够结合人血清白蛋白的氨基酸序列; 化合物，蛋白质，多肽，融合蛋白或包含或基本上由此类氨基酸序列组成的构建体; 编码这种氨基酸序列的核酸，化合物，蛋白质，多肽，融合蛋白或构建体; 包括这样的氨基酸序列，化合物，蛋白质，多肽，融合蛋白或构建体的组合物，特别是药物组合物; 以及这些氨基酸序列，化合物，蛋白质，多肽，融合蛋白或构建体的使用。

7. 发明申请

WO2017087587A1 PD1/CTLA4 Binders 审中-公开
标题翻译： PD1 / CTLA4粘合剂
公开(公告)号：WO2017087587A1
公开(公告)日：2017-05-26
申请号：PCT/US2016/062391
申请日：2016-11-17
申请人： MERCK SHARP & DOHME CORP. , PUNNONEN, Juha , BOWMAN, Edward , BEAUMONT, Maribel , BUYSE, Marie-Ange , BOUTTON, Carlo , DOMBRECHT, Bruno , VICTOR, Bjorn , VLERICK, David
发明人： PUNNONEN, Juha , BOWMAN, Edward , BEAUMONT, Maribel , BUYSE, Marie-Ange , BOUTTON, Carlo , DOMBRECHT, Bruno , VICTOR, Bjorn , VLERICK, David
IPC分类号： C07K16/18 , C07K16/28 , A61K39/395
CPC分类号： C07K16/2818 , A61K39/3955 , A61K39/39558 , A61K2039/505 , A61K2039/507 , A61K2039/54 , A61K2039/545 , C07K16/18 , C07K2317/22 , C07K2317/24 , C07K2317/31 , C07K2317/33 , C07K2317/34 , C07K2317/565 , C07K2317/569 , C07K2317/62 , C07K2317/76 , C07K2317/92 , Y02A50/403
摘要： The present invention provides multispecific molecules, e.g. , comprising more than one ISVD or Nanobody, that bind to PD1 and CTLA4. These molecules have been engineered so as to reduce the incidence of binding by pre-existing antibodies in the bodies of a subject administered such a molecule. Methods for increasing immune response, treating cancer and/or treating an infectious disease with such molecules are provided.
摘要翻译：本发明提供了多特异性分子，例如包含与PD1和CTLA4结合的超过一种ISVD或纳米抗体。已经对这些分子进行了工程改造，从而降低施用这种分子的受试者体内预先存在的抗体的结合发生率。提供了增加免疫应答，治疗癌症和/或用这些分子治疗感染性疾病的方法。

8. 发明申请

WO2017087589A3 PD1 AND/OR LAG3 BINDERS 审中-公开
公开(公告)号：WO2017087589A3
公开(公告)日：2017-05-26
申请号：PCT/US2016/062394
申请日：2016-11-17
申请人： MERCK SHARP & DOHME CORP. , BOWMAN, Edward , BEAUMONT, Maribel , BUYSE, Marie-Ange , BOUTTON, Carlo , DOMBRECHT, Bruno , VLERICK, David , KASTELEIN, Robert A.
发明人： BOWMAN, Edward , BEAUMONT, Maribel , BUYSE, Marie-Ange , BOUTTON, Carlo , DOMBRECHT, Bruno , VLERICK, David , KASTELEIN, Robert A.
IPC分类号： C07K16/28 , C07K16/18
摘要： The present invention provides molecules, such as ISVDs and Nanobodies, that bind to PD1 and LAG3 and, optionally to human serum albumin. These molecules have been engineered so as to reduce the incidence of binding by pre-existing antibodies in the bodies of a subject administered such a molecule. Methods for increasing immune response, treating cancer and/or treating an infectious disease with such molecules are provided.

9. 发明申请

WO2017087589A2 PD1 AND/OR LAG3 BINDERS 审中-公开
标题翻译： PD1和/或LAG3结合剂
公开(公告)号：WO2017087589A2
公开(公告)日：2017-05-26
申请号：PCT/US2016/062394
申请日：2016-11-17
申请人： MERCK SHARP & DOHME CORP. , BOWMAN, Edward , BEAUMONT, Maribel , BUYSE, Marie-Ange , BOUTTON, Carlo , DOMBRECHT, Bruno , VLERICK, David
发明人： BOWMAN, Edward , BEAUMONT, Maribel , BUYSE, Marie-Ange , BOUTTON, Carlo , DOMBRECHT, Bruno , VLERICK, David
IPC分类号： C07K16/28 , C07K16/18
CPC分类号： C07K16/2803 , A61K39/3955 , A61K45/06 , C07K16/18 , C07K16/2818 , C07K16/468 , C07K2317/22 , C07K2317/24 , C07K2317/31 , C07K2317/33 , C07K2317/34 , C07K2317/565 , C07K2317/569 , C07K2317/62 , C07K2317/76 , C07K2317/92
摘要： The present invention provides molecules, such as ISVDs and Nanobodies, that bind to PD1 and LAG3 and, optionally to human serum albumin. These molecules have been engineered so as to reduce the incidence of binding by pre-existing antibodies in the bodies of a subject administered such a molecule. Methods for increasing immune response, treating cancer and/or treating an infectious disease with such molecules are provided.
摘要翻译：本发明提供结合PD1和LAG3以及任选结合人血清白蛋白的分子，例如ISVD和纳米抗体。已经对这些分子进行了工程改造，从而降低施用这种分子的受试者体内预先存在的抗体的结合发生率。提供了增加免疫应答，治疗癌症和/或用这些分子治疗感染性疾病的方法。

10. 发明申请

WO2017087588A1 CTLA4 BINDERS 审中-公开
公开(公告)号：WO2017087588A1
公开(公告)日：2017-05-26
申请号：PCT/US2016/062393
申请日：2016-11-17
申请人： MERCK SHARP & DOHME CORP. , PUNNONEN, Juha , BEAUMONT, Maribel , BUYSE, Marie-Ange , BOUTTON, Carlo , DOMBRECHT, Bruno , VICTOR, Bjorn
发明人： PUNNONEN, Juha , BEAUMONT, Maribel , BUYSE, Marie-Ange , BOUTTON, Carlo , DOMBRECHT, Bruno , VICTOR, Bjorn
IPC分类号： C07K16/18 , C07K16/28 , A61K39/395
CPC分类号： C07K16/2818 , A61K39/3955 , A61K39/39558 , A61K2039/505 , A61K2039/54 , A61K2039/545 , C07K14/765 , C07K16/18 , C07K2317/22 , C07K2317/24 , C07K2317/31 , C07K2317/32 , C07K2317/33 , C07K2317/34 , C07K2317/35 , C07K2317/565 , C07K2317/569 , C07K2317/62 , C07K2317/76 , C07K2317/92 , C07K2319/31
摘要： The present invention provides molecules, such as ISVDs and Nanobodies, that bind to CTLA4 or human serum albumin. These molecules have been engineered so as to reduce the incidence of binding by pre-existing antibodies in the bodies of a subject administered such a molecule. Methods for increasing immune response, treating cancer and/or treating an infectious disease with such molecules are provided.
摘要翻译：本发明提供了结合CTLA4或人血清白蛋白的分子，例如ISVD和纳米抗体。已经对这些分子进行了工程改造，从而降低施用这种分子的受试者体内预先存在的抗体的结合发生率。提供了增加免疫应答，治疗癌症和/或用这些分子治疗感染性疾病的方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式